Therapeutic efficacy of milbemycin oxime/praziquantel oral formulation (Milbemax®) against Thelazia callipaeda in naturally infested dogs and cats

Particle and Fibre Toxicology

Domenico Otranto⁷  Filipe Dantas-Torres⁶  Riccardo P Lia⁷  Egidio Mallia¹  Brigitte Schiessl²  Catherine Nägeli⁴  Fabio Nägeli⁴  Fabrizio Solari Basano³  Manuela Schnyder⁵  Bruna Motta⁴ 

[1] Parco Regionale Gallipoli Cognato e Piccole Dolomiti Lucane, Basilicata, MT, Italy;Novartis Animal Health Inc., Schwarzwaldallee 215, CH-4058, Basel, Switzerland;Arcoblu s.r.l., Via Cardinale Mezzofanti 14, I-20133, Milan, Italy;Veterinary Clinic, Via San Gottardo 128, CH-6828, Balerna, Switzerland;Institute of Parasitology, Vetsuisse Faculty, University of Zurich, Winterthurerstr. 266a, CH-8057, Zurich, Switzerland;Departamento de Imunologia, Centro de Pesquisas Aggeu Magalhães (Fiocruz- PE), Pernambuco, Recife, Brazil;Department of Veterinary Public Health, Faculty of Veterinary Medicine, University of Bari, Str. Prov. Casamassima Km 3, I-70010, Valenzano, Bari, Italy

关键词: Treatment;    Cats;    Dogs;    Milbemycin oxime;    Thelazia callipaeda;   

Others  :  1232472
DOI  :  10.1186/1756-3305-5-85

 received in 2012-02-02, accepted in 2012-04-27,  发布年份 2012

【 摘 要 】

Background

Over the last few decades, canine and feline thelaziosis caused by Thelazia callipaeda eye worms has gained the attention of the veterinary community due to the spread of this ocular infestation in geographical areas previously regarded as non endemic. The therapeutic efficacy of milbemycin oxime/praziquantel tablets (Milbemax®) against T. callipaeda was tested in naturally infested dogs and cats.

Methods

From January 2009 to July 2011 a placebo controlled and randomized field study was conducted in T. callipaeda endemic areas of Switzerland (CH) and Italy (ITA) involving client-owned animals. Dogs (n = 56) and cats (n = 31) were physically examined at enrolment Day 0 (D0) and twice afterwards (D7 and D14). Infested animals were orally treated with Milbemax® or with placebo tablets on D0 and, if an animal was found still infested with T. callipaeda, also on D7. On D14 nematodes were flushed from the conjunctiva, identified and counted.

Results

Out of 56 dogs, 43 were included in the statistical analysis, whereas 13 were excluded because the products under investigation were not administered with food, as required by the label. On D7 and D14, 72.7% and 90.9% of treated dogs were eye worm free, whereas in the placebo group 95.2% and 76.2% still harbored nematodes, resulting in a mean percentage worm count reduction for the Milbemax® group of 86.1% and 96.8%, respectively. Both results were significantly higher (p = 0.0001) than the placebo group. Out of the 31 cats included in the study at D7 and D14, 53.3% and 73.3% treated with Milbemax® were free of T. callipaeda, while 81.3% and 73.3 in the placebo group were still harbouring eye worms, resulting in a mean percentage worm count reduction for the treated group of 62.2% and 80.0%, respectively. Both results were significantly higher (p = 0.0106 and p = 0.0043) than the placebo group.

Conclusions

The commercial formulation of milbemycin oxime at the minimal dose of 0.5 mg/kg and 2 mg/k in dogs and cats, respectively, showed a high therapeutic efficacy in curing T. callipaeda infestations. The advantages of an oral application are additionally increased by the large spectrum of activity of praziquantel and milbemycin oxime against Cestodes and Nematodes infesting dogs and cats.

【 授权许可】

   
2012 Motta et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Anderson RC: Nematode parasites of vertebrates. Their development and transmission. CABI publishing Guilford, UK; 2000:404-407.
• [2]Bhaibulaya M, Prasertsilpa S, Vajrasthira S: Thelazia callipaedaRailliet and Henry, 1910, in man and dog in Thailand. AmJTrop Med Hyg 1970, 19:476-479.
• [3]Shi YE, Han JJ, Yang WY, Wei DX: Thelazia callipaeda(Nematoda: Spirurida): transmission by flies from dogs to children in Hubei, China. Trans Royal Soc Trop Med Hyg 1988, 82:627.
• [4]Koyama Y, Ohira A, Kono T, Yoneyama T, Shiwaku K: Five cases of thelaziasis. British J Ophthalm 2000, 84:441.
• [5]Otranto D, Dantas-Torres F, Mallia E, Digeronimo PM, Brianti E, Testini G, Traversa D, Lia RP: Thelazia callipaeda(Spirurida, Thelaziidae) in wild animals: Report of new host species and ecological implications. Vet Parasitol 2009, 166:262-267.
• [6]Otranto D, Ferroglio E, Lia RP, Traversa D, Rossi L: Current status and epidemiological observation ofThelazia callipaeda(Spirurida, Thelaziidae) in dogs, cats and foxes in Italy: a “coincidence” or a parasitic disease of the Old Continent? Vet Parasitol 2003, 116:315-325.
• [7]Malacrida F, Hegglin D, Bacciarini L, Otranto D, Nageli F, Nageli C, Bernasconi C, Scheu U, Balli A, Marenco M, et al.: Emergence of canine ocular thelaziosis caused byThelazia callipaedain southern Switzerland. Vet Parasitol 2008, 157:321-327.
• [8]Dorchies P, Chaudieu G, Siméon LA, Cazalot G, Cantacessi C, Otranto D: First reports of autochthonous eyeworm infection byThelazia callipaeda(Spirurida, Thelaziidae) in dogs and cat from France. Vet Parasitol 2007, 149:294-297.
• [9]Ruytoor P, Dean E, Pennant O, Dorchies P, Chermette R, Otranto D, Guillot J: Ocular thelaziosis in dogs, France. Emerg Infect Dis 2010, 16:1943-1945.
• [10]Hermosilla C, Herrmann B, Bauer C: First case ofThelazia callipaedainfection in a dog in Germany. Vet Rec 2004, 154:568-569.
• [11]Magnis J, Naucke TJ, Mathis A, Deplazes P, Schnyder M: Local transmission of the eye wormThelazia callipaedain southern Germany. Parasitol Res 2010, 106:715-717.
• [12]Miro G, Montoya A, Hernandez L, Dado D, Vazquez MV, Benito M, Villagrasa M, Brianti E, Otranto D: Thelazia callipaeda: infection in dogs: a new parasite for Spain. Parasit Vectors 2011, 4:148.
• [13]Otranto D, Dutto M: Human Thelaziasis, Europe. Emerg Infect Dis 2008, 14:647-649.
• [14]Otranto D, Lia RP, Cantacessi C, Testini G, Troccoli A, Shen JL, Wang ZX: Nematode biology and larval development ofThelazia callipaeda(Spirurida, Thelaziidae) in the drosophilid intermediate host in Europe and China. Parasitol 2005, 131:847-855.
• [15]Otranto D, Brianti E, Cantacessi C, Lia R, Màca J: The zoophilic fruitflyPhortica variegata: morphology, ecology and biological niche. Med Vet Entomol 2006, 20:358-364.
• [16]Otranto D, Eberhard ML: Zoonotic helminths affecting the human eye. Parasit Vecors 2011, 4:41.
• [17]Otranto D, Lia RP, Buono V, Traversa D, Giangaspero A: Biology of Thelazia callipaeda(Spirurida, Thelaziidae) eyeworms in naturally infected definitive hosts. Parasitol 2004, 129:627-633.
• [18]Lia RP, Traversa D, Agostini A, Otranto D: Field efficacy of moxidectin 1 per cent againstThelazia callipaedain naturally infected dogs. Vet Rec 2004, 154:143-145.
• [19]Rossi L, Rigano C, Tomio E, Frassetto D, Ferroglio E: Use of sustained-release moxidectin to prevent eyeworm (Thelazia callipaeda) infection in dogs. Vet Rec 2007, 161:820-821.
• [20]Bianciardi P, Otranto D: Treatment of dog thelaziosis caused by Thelazia callipaeda (Spirurida, Thelaziidae) using a topical formulation of imidacloprid 10 % and moxidectin 2.5 %. Vet Parasitol 2005, 129:89-93.
• [21]Ferroglio E, Rossi L, Tomio E, Schenker R, Bianciardi P: Therapeutic and prophylactic efficacy of milbemycin oxime (Interceptor) againstThelazia callipaedain naturally exposed dogs. Vet Parasitol 2008, 154:351-353.
• [22]Bussiéras J, Chermette R, Seillier A-M: Quelques parasitoses canines exceptionelles en France. II - Un cas de conjonctivite parasitaire du chien, due àThelaziasp. Prat Méd Chir Animal Compagn 1996, 31:83-85.
• [23]Kozlov DP: The life cycle of nematodeThelazia callipaedaparasitic in the eye of the man and carnivores. Doklady Akademy Nauk SSSR 1962, 142:732-733.